KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...
KalVista granted orphan drug designation for sebetralstat by MHLW
KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The ...
KalVista Announces Orphan Drug Designation And NDA Submission For Sebetralstat In Japan
KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted ...
Japan grants orphan drug status to HAE treatment
CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ: NASDAQ:KALV) has received Orphan Drug ...
Le Lézard1d
Aldevron Unveils Next-Generation Alchemytm Cell-Free DNA Technology for Research Grade Applications
Aldevron, a global leader in the production of DNA, RNA and protein, has launched its latest innovation, Alchemytm cell-free DNA technology. This revolutionary technology represents a significant ...
Le Lézard1d
Audiencerate Announces Its Partnership With V-Valley
Audiencerate, an innovative technology company, leader in the development of advanced solutions for digital marketing (MarTech) and online advertising (AdTech) announces that it has signed a ...
PE Hub5d
Medical genetics: 5 PE-backed deals
Archimed, KKR and Novo Holdings are among the PE firms investing in pharma research, development and sales for genetic medicine.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Acquired by Barclays PLC
Barclays PLC increased its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 418.5% during the third quarter, Holdings Channel.com reports. The fund owned 67,222 ...
pharmaphorum3d
Intellia trumpets CRISPR drug data, but shares fall
including KalVista Pharma's recently filed oral plasma kallikrein inhibitor sebetralstat. The lead investigator in the phase 2 trial, Danny Cohn of Amsterdam University Medical Center in the ...